PlexusDx's Precision Peptide Genetic Test analyzes your GIPR, FTO, and MC4R variants to reveal your genetic predisposition toward tirzepatide responsiveness
Novo Nordisk this year announced a $4bn (3bn) investment in a production plant in the US to grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases
This architecture enhances dermal retention, improves apparent solubility of poorly water-soluble drugs, protects labile molecules, and minimizes systemic exposure
Most people find that the discomfort improves over time, especially if they stay hydrated, maintain a healthy diet, and stay active
Perfect to target stubborn fat deposits, enhance fat breakdown in the liver, and boost energy production